Estrogen-receptor biology: continuing progress and therapeutic implications.

Endocrine therapies, first used more than 100 years ago, are the most effective treatments for breast cancers expressing the estrogen receptor (ER). All endocrine therapies are designed to block ER function in some way, thereby making them the first targeted therapies used for cancer. Selective ER modulators (SERMs) such as tamoxifen bindERandpartially block its activity.Ovarian ablation, luteinizing hormone–releasing hormone agonists, and aromatase inhibitors reduce the level of estrogen and inhibit ligand-induced activation of ER. Steroidal antiestrogens such as fulvestrant bind ER, more completely block its function, and induce receptor degradation.While all of these therapies are effective in certain patients, de novo and acquired resistance remain major problems. New information on the biology of ER provides insight into the mechanisms of treatment resistance and new strategies to overcome it, thereby potentially making these therapies even more effective.

[1]  P. Meltzer,et al.  AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. , 1997, Science.

[2]  P. Chambon,et al.  Cloning of the human oestrogen receptor cDNA. , 1986, Journal of steroid biochemistry.

[3]  D B Evans,et al.  Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  E. Levin.  Cellular functions of plasma membrane estrogen receptors , 2002, Steroids.

[5]  C. Powers,et al.  Ribozyme Targeting Demonstrates That the Nuclear Receptor Coactivator AIB1 Is a Rate-limiting Factor for Estrogen-dependent Growth of Human MCF-7 Breast Cancer Cells* , 2001, The Journal of Biological Chemistry.

[6]  J. Font de Mora,et al.  AIB1 Is a Conduit for Kinase-Mediated Growth Factor Signaling to the Estrogen Receptor , 2000, Molecular and Cellular Biology.

[7]  R. McPherson,et al.  Linkage of Rapid Estrogen Action to MAPK Activation by ER-Shc Association and Shc Pathway Activation , 2001 .

[8]  T. Archer,et al.  Upstream stimulatory factors mediate estrogen receptor activation of the cathepsin D promoter. , 1998, Molecular endocrinology.

[9]  Heidi L. Weiss,et al.  Low Levels of Estrogen Receptor β Protein Predict Resistance to Tamoxifen Therapy in Breast Cancer , 2004, Clinical Cancer Research.

[10]  M. Dowsett,et al.  Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive operable breast cancer in postmenopausal women The IMPACT Trial , 2003 .

[11]  S. Hilsenbeck,et al.  Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.

[12]  R. Schiff,et al.  Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.

[13]  R. Lanz,et al.  Nuclear receptor coregulators: cellular and molecular biology. , 1999, Endocrine reviews.

[14]  P. Chambon,et al.  Cloning of the human estrogen receptor cDNA. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Mass.  The role of HER-2 expression in predicting response to therapy in breast cancer. , 2000, Seminars in oncology.

[17]  E. Filardo,et al.  Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[18]  Lei Li,et al.  Plasma membrane localization and function of the estrogen receptor α variant (ER46) in human endothelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  R. Schiff,et al.  Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. , 2000, Journal of the National Cancer Institute.

[20]  John Calvin Reed,et al.  Mechanisms of Transcriptional Activation of bcl-2Gene Expression by 17β-Estradiol in Breast Cancer Cells* , 1999, The Journal of Biological Chemistry.

[21]  M. Dowsett,et al.  Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  R. Pietras,et al.  Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells , 1977, Nature.

[23]  R. Elledge,et al.  Molecular markers for predicting response to tamoxifen in breast cancer patients , 2000, Endocrine.

[24]  S. Jiang,et al.  Estrogen receptor corepressors -- a role in human breast cancer? , 2003, Endocrine-related cancer.

[25]  E. Levin.  highlighted topics Genome and Hormones: Gender Differences in Physiology Invited Review: Cell localization, physiology, and nongenomic actions of estrogen receptors , 2001 .

[26]  D. Heitjan,et al.  Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. , 1995, The Journal of clinical endocrinology and metabolism.

[27]  A. Ray,et al.  Repression of interleukin‐6 gene expression by 17β‐estradiol: , 1997 .

[28]  Gene regulation by steroid hormones , 1989, Cell.

[29]  K. Horwitz,et al.  Nuclear receptor coactivators and corepressors. , 1996, Molecular endocrinology.

[30]  B. Katzenellenbogen,et al.  The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. , 1995, Molecular endocrinology.

[31]  D. Agard,et al.  Estrogen receptor pathways to AP-1 , 2000, The Journal of Steroid Biochemistry and Molecular Biology.

[32]  R. Vadlamudi,et al.  Functional Interactions between the Estrogen Receptor Coactivator PELP1/MNAR and Retinoblastoma Protein* , 2003, Journal of Biological Chemistry.

[33]  L. Altucci,et al.  17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. , 1996, Oncogene.

[34]  E. Levin.  Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. , 2003, Molecular endocrinology.

[35]  R. Nicholson,et al.  Modulation of Epidermal Growth Factor Receptor in Endocrine‐Resistant, Estrogen‐Receptor‐Positive Breast Cancer , 2002, Annals of the New York Academy of Sciences.

[36]  K. Horwitz,et al.  Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors , 1999, The Journal of Steroid Biochemistry and Molecular Biology.

[37]  K. Ley,et al.  Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase , 2000, Nature.

[38]  M. van Eickels,et al.  Estrogen Receptor α Rapidly Activates the IGF-1 Receptor Pathway* , 2000, The Journal of Biological Chemistry.

[39]  N. McKenna,et al.  Distinct steady-state nuclear receptor coregulator complexes exist in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  H. Selye.  CORRELATIONS BETWEEN THE CHEMICAL STRUCTURE AND THE PHARMACOLOGICAL ACTIONS OF THE STEROIDS1 , 1942 .

[41]  J. Liao,et al.  Nonnuclear actions of estrogen. , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[42]  M. Privalsky,et al.  The SMRT Corepressor Is Regulated by a MEK-1 Kinase Pathway: Inhibition of Corepressor Function Is Associated with SMRT Phosphorylation and Nuclear Export , 2000, Molecular and Cellular Biology.

[43]  A. Bilancio,et al.  PI3‐kinase in concert with Src promotes the S‐phase entry of oestradiol‐stimulated MCF‐7 cells , 2001, The EMBO journal.

[44]  S. Safe.  Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. , 2001, Vitamins and hormones.

[45]  S. Hilsenbeck,et al.  Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth , 2002, Oncogene.

[46]  R. Laucirica,et al.  Estrogen receptor beta expression in invasive breast cancer. , 2001, Human pathology.

[47]  R. Schiff,et al.  Estrogen receptor: current understanding of its activation and modulation. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  B. O’Malley,et al.  Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. , 1997, Molecular endocrinology.

[49]  Myles Brown,et al.  Molecular Determinants for the Tissue Specificity of SERMs , 2002, Science.

[50]  C. J. Barnes,et al.  A naturally occurring MTA1 variant sequesters oestrogen receptor-α in the cytoplasm , 2002, Nature.

[51]  P. Chambon,et al.  Modulation of transcriptional activation by ligand‐dependent phosphorylation of the human oestrogen receptor A/B region. , 1993, The EMBO journal.

[52]  Woong Sun,et al.  Estrogen‐induced cyclin D1 and D3 gene expressions during mouse uterine cell proliferation in vivo: Differential induction mechanism of cyclin D1 and D3 , 1997, Molecular reproduction and development.

[53]  B. Katzenellenbogen,et al.  Transcription Activation by the Human Estrogen Receptor Subtypeβ (ERβ) Studied with ERβ and ERα Receptor Chimeras* *This work was supported by NIH Grants CA-18119 and CA-60514 (to B.S.K.). , 1998, Endocrinology.

[54]  A. Sahin,et al.  Molecular Cloning and Characterization of PELP1, a Novel Human Coregulator of Estrogen Receptor α , 2001 .

[55]  C K Osborne,et al.  Selective estrogen receptor modulators: structure, function, and clinical use. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  E. Falkenstein,et al.  Nongenomic steroid action: controversies, questions, and answers. , 2003, Physiological reviews.

[57]  M. Southey,et al.  Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. , 2001, Cancer research.

[58]  X. Guan,et al.  Her2/neu Expression Predicts the Response to Antiaromatase Neoadjuvant Therapy in Primary Breast Cancer , 2004, Clinical Cancer Research.

[59]  G. Figtree,et al.  Truncated Estrogen Receptor &agr; 46-kDa Isoform in Human Endothelial Cells: Relationship to Acute Activation of Nitric Oxide Synthase , 2003, Circulation.